


# **MULTINODULAR GOITER AND DIFFERENTIATED** P2-932 **THYROID CANCER IN PEDIATRICS**



Papendieck P<sup>1</sup>, Venara M<sup>1</sup>, Elias E<sup>2</sup>, Cozzani H<sup>3</sup>, Mateos F<sup>3</sup>, Maglio S<sup>4</sup>, Calcagno ML<sup>5</sup>, Gruñeiro-Papendieck L<sup>1</sup>, Bergadá I<sup>1</sup>, Chiesa A<sup>1</sup>

<sup>1</sup> Centro de Investigaciones Endocrinológicas Dr. César Bergadá - CONICET – Division of Endocrinology <sup>2</sup> Surgery Department, <sup>3</sup> Radiology Department, <sup>4</sup> Pathological Anatomy Department, "Cr. Ricardo Gutiérrez" Children's Hospital <sup>5</sup> Chair of Mathematics. School of Pharmacy and Biochemistry, University of Buenos Aires. Buenos Aires-Argentina

## INTRODUCTION

Multinodular goiter (MNG) defined as an enlarged thyroid gland with two or more thyroid nodules have historically been thought of as a benign condition with a low risk of associated malignancy.

Thyroid nodules in childhood and adolescence have an estimated prevalence up to 1.8% with a greater malignancy risk than in adults.

In a recent report we have identified multinodular goiter (MNG) as a condition with an increased risk for thyroid malignancy in children and adolescents.

> DTC in Children: Prevalence and Predictors in a Large Cohort with Thyroid Nodules Followed Prospectively . P Papendieck et al. J Pediatr 2015

## **OBJECTIVES**

•To report the prevalence and characterization of a prospectively and uniformly followed cohort of pediatric patients with MNG


•To analyze the differences between benign and malignant BMN before surgery in order to identify malignancy predictors.

## RESULTS

## DIFFERENCES BETWEEN BENIGN AND MALIGNANT MNG

#### How to approach MNG is controversial both in children and adults.

#### **MATERIAL AND METHODS**



	BENIGN	MALIGNANT	P VALUE
	24	8	
CLINICAL DATA			
Age	<b>14.6</b>	10.4	.04
(years, median, range)	(8-18.5)	(11.2-16.9)	
₽ <b>/</b> ♂	20/4	4/4	.08
Prepubertal	5(21%)	5 (62.5%)	.035
Risk factors	5	_	
Goiter type			
Palpable MNG	21	7	
Non palpable			
Diffuse Goiter	3	_	
Normal thyroid	-	1	
Palpable lymph nodes	-	1	
ABORATORY (n:23)			
TSH	1.42	3.5	.04
/mIU/L, median,range)	(.01-13.5)	(1.6-8.4)	
Thyroid function	, , , , , , , , , , , , , , , , , , ,		
Normal	13	6	
Hypothyroidism	1	2	
Hyperthyroidism	-	_	
Thyroid Ab	- 6/23 (26%)	1/8 (12.5%)	
US	0/20 (20/0)	1/0 (12.370)	
<u>Dominant nodule size</u>	17.4	20.5	
(mm, median,range)	(8-48)	(2-80)	
Solid	12 (50%)	8 (100%)	.02
Mixed/cystic	12 (3070)	-	.02
Irregular margins	2	2	.01
Intranod. Microcalcific.	2	2	
Intranodular flow	5 13 (54%)	J A (50%)	
Path. adenopathies	15 (5470)	4 (50%) <b>4 (50%)</b>	< .01
rutil. udenoputilies	-	4 (JU/0)	<b>\.U1</b>
	<u>%</u>		_
9- <sup>10</sup> p <.05	100		
$ \begin{array}{c} P \\ \bullet \\ \bullet \end{array} \end{array} $	80		Rising TSH levels
7-			- associated with M
100 F			( <i>p&lt;0.05</i> )
	40		
∯ 4- <b>•</b>			Benign
$\begin{array}{c} & & & \\ & & \\ & & 3 \end{array}$	20		_ Benign Malignant
	20		Malignant
	20 0	0.40-1.39 1.40-2.49 2.50-4.99 5.00-10.00	
3 2 1 1 0 BENIGN MALIGNANT	20 		Malignant TSH (mIU/L)
3 2 1 0 BENIGN MALIGNANT CYTOLOGY-FINAL DIAC	20 		Malignant TSH (mIU/L) ADULTS
	0 0 	RELATION (n:31)	Malignant TSH (mIU/L) ADULTS
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup>	 Definition of the second	<b>RELATION (n:31)</b> MALIGNANT MALIGNANCY RA	Malignant TSH (mIU/L) ATE (%)
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup>	 Definition of the second	RELATION (n:31) MALIGNANT MALIGNANCY RA	Malignant TSH (mIU/L) ATE (%) 1-4
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup>	      	<b>RELATION (n:31)</b> MALIGNANT MALIGNANCY RA - 0 1 7.7	Malignant TSH (mIU/L) ATE (%) 1-4 0-3
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup>	 Definition of the second	<b>RELATION (n:31)</b> MALIGNANT MALIGNANCY RA - 0 1 7.7 - 0	Malignant TSH (mIU/L) <b>ATE (%)</b> 1-4 0-3 5-10
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup>	      	RELATION (n:31)   MALIGNANT MALIGNANCY RA   - 0   1 7.7   - 0   - 0   - 0   - 0   - 0   - 0	Malignant TSH (mIU/L) ATE (%) 1-4 0-3
<sup>3</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>2</sup> <sup>2</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>2</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup> <sup>1</sup>	      	<b>RELATION (n:31)</b> MALIGNANT MALIGNANCY RA - 0 1 7.7 - 0	Malignant TSH (mIU/L) <b>ATE (%)</b> 1-4 0-3 5-10

## **INITIAL EVALUATION:** CLINICAL DATA THYROID FUNCTION ■*CERVICAL DOPPLER –US* ■US-GUIDED FNAB (BETHESDA)

✓ FROZEN SECTION (to confirm preoperative FNAB and decide the extent of the surgery CND) ✓ *HISTOPATHOLOGICAL ANALYSIS* 

✓ ANALYSIS OF DIFFERENCES BETWEEN BENIGN AND MALIGNANT MNG

#### STATISTICAL ANALYSIS

Statistical analysis by Student t test and Chi-squared test. Univariate and multiple binary logistic regression analyses were used to evaluate the independent influence of age, gender, pubertal status, thyroid-Ab, TSH as continuous variable and within designated ranges . p<0.05 was considered significant. SPSS 18.0 (Chicago, Illinois) & InfoStat (Univ.Nac.Córdoba).

## SUMMARY

- ✓ MNG represented 31% of our thyroid nodule population.
- ✓ PTC was the only malignant histotype with an incidence of 25%, similar to that reported in pediatric thyroid nodules globally.
- ✓ Younger age, prepubertal status, higher TSH concentration even within normal range, solid nodules and pathologic cervical lymph nodes were significantly associated with malignancy.
- ✓ Mixed or cystic MNG were significantly associated with benignancy. ✓ Malignancy rates using Bethesda were similar to adults.

#### **PATHOLOGICAL ANALYSIS (n:24)** NODULAR HYPERPLASIA 15 MULTIPLE FOLLICULAR ADENOMA PAPILLARY THYROID CARCINOMA

Cibas and All Am J Clin Pathol 2009;132:658-665

### **CONCLUSIONS**

This study confirms our previous report about malignancy risk of pediatric MNG. According to our findings this condition has to be faced as every pediatric thyroid nodule with a systematic approach in which each diagnostic tool provides useful information to reach diagnosis.

Disclosure Statement: This study was not funded. The authors declare that no competing financial interests exist.

